Consider the fact that Sanofi invests in awareness initiatives throughout Latin America, Africa and the Asia-Pacific area (to name a few). As a result, the firm provides items in certain locations at a reduced price to make them more affordable. This market development is further aided by new product releases and regulatory approvals, such as that of UCB Pharma's Vimpat medication approvals in Europe and Japan for treating partial-onset seizures in 2016.
During the projected period, the market for anti-epileptic medicines for pediatrics is predicted to expand due to the increasing prevalence of epilepsy. The American Academy of Pediatrics reports that epilepsy is the most prevalent brain illness in children, with almost 3 million Americans suffering from it in 2016. (450,000 of which are under the age of 17).
Drug-resistant epilepsy is a growing problem, and major companies are working to provide effective treatment choices for sufferers. Additional or adjunctive treatments have considerable beneficial benefits with considerably fewer adverse effects than standard treatments do. As a result of this, anti-epileptic medicines are likely to see a huge spurt. Lyrica (pregabalin), for example, is a promising medication with fewer drug interactions, better side effect profiles, and increased overall safety. As a result, the market is expected to grow strongly, since older treatments, such as carbamazepine, valproate, and phenytoin, are not well tolerated by pediatric patients despite being effective.